Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
Recruiting · NCT07087223 · Registry updated 2025-07-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure | Non Small Cell Lung Cancer NSCLC | Recruiting | Phase 1 / Phase 2 | 2025-07-25 | NCT07087223 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking University Cancer Hospital & Institute | 189 |
12 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Affiliated Hospital of Hebei University | Baoding | China | 8 |
| Baotou Cancer Hospital | Baotou | China | 1 |
| Beijing Chest Hospital, Capital Medical University | Beijing | China | 7 |
| Beijing Daxing District People's Hospital | Beijing | China | 3 |
| Ordos Central Hospital | Neimeng | China | 1 |
| Peking Union Medical College Hospital | Beijing | China | 112 |
| Peking University Cancer Hospital & Institute | Beijing | China | 3 |
| Peking University Cancer Hospital (Inner Mongolia Campus) | Neimeng | China | 1 |
| Peking University People's Hospital | Beijing | China | 68 |
| Peking University Third Hospital | Beijing | China | 71 |
| The Second Hospital of Dalian Medical University | Dalian | China | 8 |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin | China | 50 |